- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00348881
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
Large Scale Safety and Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix HepB/Hib™, Both Given Concomitantly With OPV at 6, 10, and 14 Weeks of Age in Healthy Filipino Infants
연구 개요
상태
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Corporate City, 필리핀 제도
- Filinvest
-
-
Muntinlupa City
-
Alabang, Muntinlupa City, 필리핀 제도
-
Putatan,, Muntinlupa City, 필리핀 제도
-
Tunasan,, Muntinlupa City, 필리핀 제도
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
At Screening:
- 0 to 3 day old infants
- Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg
- Apgar score ≥ 7 at three minutes after birth
- Informed consent form signed by one parent or legal representative if appropriate (independent witness mandatory if parent is illiterate)
At Inclusion:
- Six weeks of age
- Received a dose of Hepatitis B (HB) in the first three days of life
- Able to attend all scheduled visits and to comply with all trial procedures.
Exclusion Criteria:
At Screening:
- Illness at a stage that could interfere with trial conduct or completion
- Any vaccination before HB vaccination (except bacille Calmette-Guérin [BCG] given at birth)
- Vaccination planned in the 4 to 6 weeks following the first trial vaccination (except BCG if not given at birth)
- Acute illness on the day of screening.
At Screening and at Inclusion:
- Blood or blood-derived products received since birth
- Planned participation in another clinical trial during the present trial period
- Mother known as seropositive to Human immunodeficiency virus (HIV) or Hepatitis C, or as carrying the HB surface antigen (HBsAg)
- Known thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
- Known hypersensitivity to any component of any vaccine to be used in the trial (including neomycin and polymixin B)
At Inclusion:
- Non-trial vaccine administered since birth, except Bacille Calmette-Guérin (BCG)
- Participation in another clinical trial before the first trial vaccination
- Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroid therapy
- Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances
- Chronic illness at a stage that could interfere with trial conduct or completion
- Vaccination other than with the study vaccines planned in the 12 weeks following inclusion
- Documented history of pertussis, tetanus, diphtheria, polio, H. influenza type b, or HB infection (confirmed clinically, serologically, or microbiologically)
- History of seizures
- Febrile (rectal temperature ≥ 38.0°C) or acute illness on the day of inclusion.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Group 1: DTaP-Hep B-PRP-T + OPV vaccine
Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
|
0.5 mL, Intramuscular
Oral co-administered with study vaccine.
|
활성 비교기: Group 2: Tritanrix-HepB/Hib™ + OPV vaccine
Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
|
Oral co-administered with study vaccine.
0.5 mL, Intramuscular
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV
기간: 1 month post third vaccination
|
Seroprotection was assessed by means of radioimmunoassay (RIA) for anti-Hepatitis B (Hep Bs) and anti-PRP antibodies, enzyme immunoassay (EIA) for anti-Tetanus, and serum neutralization (SN) for anti-Diphtheria. Seroprotection was defined as titers ≥ 10 mIU/mL for anti-Hep Bs; ≥ 0.15 μg/mL for anti-PRP; ≥ 0.01 IU/mL for anti-Tetanus and anti-Diphtheria at 30 days after the third vaccination. |
1 month post third vaccination
|
Number of Participants With Observed High Fever During the 7-Day After Vaccination With DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/ Hib™ Concomitantly With OPV.
기간: Day 0 to Day 7 post-vaccination
|
Occurence of at least one high fever episode (≥ 39.6ºC rectal temperature equivalent) observed within 7 days after any of the three injections.
|
Day 0 to Day 7 post-vaccination
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV
기간: 1 month post third vaccination
|
Immunogenicity was assessed by means of radioimmunoassay (RIA) for anti-Hepatitis B (Hep Bs) and anti-PRP antibodies; enzyme immunoassay (EIA) for anti-Tetanus; serum neutralization (SN) for anti-Diphtheria; and enzyme-linked immunosorbent assay (ELISA) for anti-Pertusiss (PT) and anti-Filamentous Hemagglutinin (FHA) titers at Day 150, 1 month after the third vaccination.
|
1 month post third vaccination
|
Number of Participants Reporting At Least One Solicited Injection Site Reaction or Systemic Reactions Following Each Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV
기간: Day 0 to Day 7 after vaccination
|
Solicited injection site reactions: Pain, Erythema, and Swelling; Solicited systemic reactions; Fever (temperature), Vomiting, Abnormal Crying, Drowsiness, Loss of Appetite, and irritability. Grade 3 reactions are defined as: Pain - cries when injected limb is moved; Erythema and Swelling - ≥ 5cm; Fever - rectal temperature ≥ 39.6ºC; Vomiting - ≥6 episodes per 24 hours; Crying - inconsolable crying for >3 hours; Somnolence - sleeping most of the time or difficulty to wake up; Anorexia - refuses ≥3 feeds; and Irritability - inconsolable. |
Day 0 to Day 7 after vaccination
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- AL201
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
B형 간염에 대한 임상 시험
-
Pfizer완전한수막구균 B 질병호주, 폴란드, 핀란드, 체코
-
Canadian Immunization Research NetworkUniversity of British Columbia; University of Calgary; Dalhousie University; Université de...완전한
-
Jiangsu HengRui Medicine Co., Ltd.모집하지 않고 적극적으로
-
Hebei Senlang Biotechnology Inc., Ltd.Tongji Hospital모병
-
Masonic Cancer Center, University of Minnesota완전한난치성 B-혈통 백혈병 | 재발된 B 계통 백혈병 | 난치성 B 계통 림프종 | 재발된 B 계통 림프종미국
-
Shanghai Tongji Hospital, Tongji University School...모병
-
Fundamenta Therapeutics, Ltd.Anhui Provincial Hospital모병
DTaP-HB-PRP~T combined vaccine에 대한 임상 시험
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비칠면조
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | B형 헤모필루스 인플루엔자페루, 멕시코
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비 | B형 헤모필루스 인플루엔자남아프리카
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비칠면조
-
Sanofi Pasteur, a Sanofi Company완전한백일해 | 파상풍 | 디프테리아 | 소아마비 | B형 헤모필루스 인플루엔자아르헨티나
-
Sanofi Pasteur, a Sanofi Company완전한
-
Sanofi Pasteur, a Sanofi Company완전한
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | 소아마비콜롬비아, 코스타리카
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | 소아마비 | 인간 면역결핍 바이러스 감염남아프리카
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | B형 헤모필루스 인플루엔자필리핀 제도